CY1113071T1 - Καππα επιλεκτικος ανταγωνιστης οπιοειδους υποδοχεα - Google Patents
Καππα επιλεκτικος ανταγωνιστης οπιοειδους υποδοχεαInfo
- Publication number
- CY1113071T1 CY1113071T1 CY20121100765T CY121100765T CY1113071T1 CY 1113071 T1 CY1113071 T1 CY 1113071T1 CY 20121100765 T CY20121100765 T CY 20121100765T CY 121100765 T CY121100765 T CY 121100765T CY 1113071 T1 CY1113071 T1 CY 1113071T1
- Authority
- CY
- Cyprus
- Prior art keywords
- optional
- competitor
- kappa
- competitive
- schizophrenia
- Prior art date
Links
- 230000002860 competitive effect Effects 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000003840 Opioid Receptors Human genes 0.000 abstract 1
- 108090000137 Opioid Receptors Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08380012 | 2008-01-22 | ||
| US3912108P | 2008-03-25 | 2008-03-25 | |
| EP09703808A EP2252581B1 (en) | 2008-01-22 | 2009-01-13 | Kappa selective opioid receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113071T1 true CY1113071T1 (el) | 2016-04-13 |
Family
ID=40876972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100765T CY1113071T1 (el) | 2008-01-22 | 2012-08-24 | Καππα επιλεκτικος ανταγωνιστης οπιοειδους υποδοχεα |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7709522B2 (https=) |
| EP (1) | EP2252581B1 (https=) |
| JP (1) | JP5345637B2 (https=) |
| KR (1) | KR101172170B1 (https=) |
| CN (1) | CN101925576B (https=) |
| AR (1) | AR070158A1 (https=) |
| AU (1) | AU2009206653B2 (https=) |
| BR (1) | BRPI0907382B8 (https=) |
| CA (1) | CA2713025C (https=) |
| CO (1) | CO6290644A2 (https=) |
| CY (1) | CY1113071T1 (https=) |
| DK (1) | DK2252581T3 (https=) |
| DO (1) | DOP2010000222A (https=) |
| EA (1) | EA017484B1 (https=) |
| EC (1) | ECSP10010365A (https=) |
| ES (1) | ES2388708T3 (https=) |
| HR (1) | HRP20120558T1 (https=) |
| IL (1) | IL206038A (https=) |
| JO (1) | JO2797B1 (https=) |
| MA (1) | MA32751B1 (https=) |
| MX (1) | MX2010007849A (https=) |
| MY (1) | MY163014A (https=) |
| NZ (1) | NZ586225A (https=) |
| PE (1) | PE20091317A1 (https=) |
| PL (1) | PL2252581T3 (https=) |
| PT (1) | PT2252581E (https=) |
| SI (1) | SI2252581T1 (https=) |
| TN (1) | TN2010000306A1 (https=) |
| TW (1) | TWI422369B (https=) |
| UA (1) | UA100715C2 (https=) |
| WO (1) | WO2009094260A1 (https=) |
| ZA (1) | ZA201003908B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091439A1 (es) * | 2008-01-22 | 2009-10-19 | Takeda Pharmaceutical | Compuestos triciclicos como antagonistas de crf |
| WO2009094260A1 (en) * | 2008-01-22 | 2009-07-30 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
| EP2757881A4 (en) | 2011-09-15 | 2014-11-12 | Univ Kansas | KAPPA OPIATE RECEPTOR EFFECTORS AND USES THEREOF |
| WO2013042054A1 (en) | 2011-09-19 | 2013-03-28 | Carmel - Haifa University Economic Corporation Ltd. | Buprenorphine for the treatment of acute suicidality |
| EP2773352B1 (en) | 2011-12-09 | 2017-06-28 | Research Triangle Institute | 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US9283196B1 (en) | 2013-01-30 | 2016-03-15 | MediSynergics, LLC | Cycloalkyl-diamines for CNS disorders |
| CA2911231C (en) * | 2013-05-24 | 2021-12-07 | Alkermes Pharma Ireland Limited | Morphan and morphinan analogues, and methods of use |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| ES2926533T3 (es) | 2017-03-17 | 2022-10-26 | Scripps Research Inst | Antagonistas del receptor opioideo kappa y productos y métodos relacionados con los mismos |
| JP6480616B1 (ja) | 2018-02-08 | 2019-03-13 | 有限会社 ディオン光学技研 | 照準スコープ |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN114195693A (zh) * | 2020-09-17 | 2022-03-18 | 广东东阳光药业有限公司 | 一种酰胺化合物的晶型及其制备方法 |
| CN114591211B (zh) * | 2020-12-04 | 2025-10-21 | 广东东阳光药业股份有限公司 | 一种酰胺化合物的共晶及其制备方法 |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| AU2022268720A1 (en) | 2021-05-04 | 2023-12-21 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| JP2025503646A (ja) * | 2022-01-10 | 2025-02-04 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | うつ病の治療のための組成物及び方法 |
| EP4463143A1 (en) * | 2022-01-10 | 2024-11-20 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| EP4489730B1 (en) | 2022-03-07 | 2026-01-21 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| WO2023170547A1 (en) * | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Pure forms of crystalline aticaprant |
| CN119156211A (zh) | 2022-03-07 | 2024-12-17 | 杨森制药公司 | 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰 |
| JP7176142B1 (ja) | 2022-03-09 | 2022-11-21 | 直迪 清瀬 | 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457208A (en) * | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
| WO2000069858A1 (en) * | 1999-05-12 | 2000-11-23 | F. Hoffmann-La Roche Ag | Imidazodiazepine derivative |
| JP2004510789A (ja) * | 2000-10-05 | 2004-04-08 | モーラー，ハンス | 選択的抗不安治療薬 |
| JP2004518654A (ja) * | 2000-12-21 | 2004-06-24 | ザ マクレーン ホスピタル コーポレーション | 鬱病の治療法 |
| US6974824B2 (en) | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| DE60319812T2 (de) * | 2002-03-28 | 2009-04-23 | Wisys Technology Foundation, Inc., Madison | Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen |
| KR101025633B1 (ko) * | 2002-09-19 | 2011-03-30 | 일라이 릴리 앤드 캄파니 | 오피오이드 수용체 안타고니스트로서의 디아릴 에테르 |
| CN1756746A (zh) * | 2003-03-07 | 2006-04-05 | 伊莱利利公司 | 作为阿片样物质受体拮抗剂的6－取代的烟酰胺衍生物 |
| US7396943B2 (en) * | 2003-03-07 | 2008-07-08 | Eli Lilly And Company | Opioid receptor antagonists |
| BRPI0417156A (pt) * | 2003-12-12 | 2007-03-06 | Lilly Co Eli | composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso |
| CN1894240A (zh) * | 2003-12-22 | 2007-01-10 | 伊莱利利公司 | 阿片受体拮抗剂 |
| AU2005222640A1 (en) * | 2004-03-12 | 2005-09-29 | The Mclean Hospital Corporation | Salvinorin derivatives and uses thereof |
| EP1727788B1 (en) * | 2004-03-12 | 2010-07-28 | Eli Lilly And Company | Opioid receptor antagonists |
| EP1730140B1 (en) * | 2004-03-12 | 2008-06-25 | Eli Lilly And Company | Opioid receptor antagonists |
| JP2007529523A (ja) * | 2004-03-15 | 2007-10-25 | イーライ リリー アンド カンパニー | 肥満症を治療するためのオピオイド受容体拮抗物質としての４−（５−アミノメチル）−インドール−１−イルメチル）−ベンズアミド誘導体および関連化合物 |
| CA2557794A1 (en) * | 2004-03-15 | 2005-10-06 | Eli Lilly And Company | Opioid receptor antagonists |
| US8551986B2 (en) * | 2005-12-08 | 2013-10-08 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| DK2001456T3 (da) | 2006-04-04 | 2010-04-12 | Emodys Gmbh | Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser |
| WO2008021849A2 (en) | 2006-08-09 | 2008-02-21 | Smithkline Beecham Corporation | Novel compounds as antagonists or inverse agonists at opioid receptors |
| US20100222345A1 (en) | 2006-08-09 | 2010-09-02 | Caroline Jean Diaz | Novel compounds as antagonists or inverse agonists for opioid receptors |
| CN101511808A (zh) | 2006-09-08 | 2009-08-19 | 辉瑞产品公司 | 二芳基醚衍生物及其用途 |
| WO2009094260A1 (en) * | 2008-01-22 | 2009-07-30 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
-
2009
- 2009-01-13 WO PCT/US2009/030811 patent/WO2009094260A1/en not_active Ceased
- 2009-01-13 JO JO200915A patent/JO2797B1/en active
- 2009-01-13 UA UAA201008931A patent/UA100715C2/ru unknown
- 2009-01-13 CN CN2009801026504A patent/CN101925576B/zh active Active
- 2009-01-13 MX MX2010007849A patent/MX2010007849A/es active IP Right Grant
- 2009-01-13 ES ES09703808T patent/ES2388708T3/es active Active
- 2009-01-13 SI SI200930326T patent/SI2252581T1/sl unknown
- 2009-01-13 AR ARP090100098A patent/AR070158A1/es not_active Application Discontinuation
- 2009-01-13 HR HRP20120558AT patent/HRP20120558T1/hr unknown
- 2009-01-13 PT PT09703808T patent/PT2252581E/pt unknown
- 2009-01-13 NZ NZ586225A patent/NZ586225A/en unknown
- 2009-01-13 DK DK09703808.7T patent/DK2252581T3/da active
- 2009-01-13 US US12/352,869 patent/US7709522B2/en active Active
- 2009-01-13 PE PE2009000036A patent/PE20091317A1/es active IP Right Grant
- 2009-01-13 KR KR1020107016401A patent/KR101172170B1/ko active Active
- 2009-01-13 EA EA201070877A patent/EA017484B1/ru not_active IP Right Cessation
- 2009-01-13 BR BRPI0907382A patent/BRPI0907382B8/pt active IP Right Grant
- 2009-01-13 JP JP2010543182A patent/JP5345637B2/ja active Active
- 2009-01-13 MY MYPI2010003437A patent/MY163014A/en unknown
- 2009-01-13 CA CA2713025A patent/CA2713025C/en active Active
- 2009-01-13 PL PL09703808T patent/PL2252581T3/pl unknown
- 2009-01-13 EP EP09703808A patent/EP2252581B1/en active Active
- 2009-01-13 AU AU2009206653A patent/AU2009206653B2/en active Active
- 2009-01-13 TW TW098101083A patent/TWI422369B/zh active
-
2010
- 2010-04-09 US US12/757,451 patent/US8173695B2/en active Active
- 2010-05-27 IL IL206038A patent/IL206038A/en active IP Right Grant
- 2010-06-01 ZA ZA2010/03908A patent/ZA201003908B/en unknown
- 2010-06-30 TN TN2010000306A patent/TN2010000306A1/fr unknown
- 2010-07-19 MA MA33041A patent/MA32751B1/fr unknown
- 2010-07-20 DO DO2010000222A patent/DOP2010000222A/es unknown
- 2010-07-22 EC EC2010010365A patent/ECSP10010365A/es unknown
- 2010-08-12 CO CO10099271A patent/CO6290644A2/es active IP Right Grant
-
2012
- 2012-08-24 CY CY20121100765T patent/CY1113071T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113071T1 (el) | Καππα επιλεκτικος ανταγωνιστης οπιοειδους υποδοχεα | |
| ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE505467T1 (de) | 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten | |
| ATE471940T1 (de) | Thienoä3,2-düpyrimidin-derivat geeignet als pi3k inhibitor | |
| EA201100306A1 (ru) | Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1 | |
| CY1116261T1 (el) | Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων | |
| BRPI0922384A2 (pt) | "manipulador de suprimento para equipamento". | |
| ATE489389T1 (de) | 2 -heteroaryl- pyrrolo ä3, 4-cüpyrrol- derivate und deren verwendung als scd inhibitoren | |
| ATE458740T1 (de) | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten | |
| UA95768C2 (ru) | Антагонисты мускариновых рецепторов ацетилхолина | |
| BRPI0922224A2 (pt) | composições de inibidores de proteína tirosina quiinase receptora. | |
| ATE526325T1 (de) | Substituierte benzimidazole als kinaseinhibitoren | |
| EP2061907A4 (en) | Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181 | |
| FR2935906B1 (fr) | Dispositif de reeducation perineale. | |
| IT1392499B1 (it) | Dispositivo di rilevamento dell'impatto. | |
| ATE544767T1 (de) | Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten | |
| EP4125244C0 (en) | HASH BASED MULTIHOSTING | |
| EP2150167A4 (en) | SEMI-DISPOSABLE ENDOSCOPE | |
| EA201170227A1 (ru) | Имидазолкарбоксамиды | |
| UY32225A (es) | Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2 | |
| UY32331A (es) | Compuestos novedosos como ligandos de receptores de canabinoides | |
| EP2349624A4 (en) | PORTABLE ELECTROERODER | |
| NI200900081U (es) | Anticuerpos agonistas de trkb y sus usos. | |
| CO6260091A2 (es) | Derivados de iminopiridina y su uso | |
| FR2944041B1 (fr) | Plateforme en encorbellement equipee d'un dispositif d'extension. |